Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1995 Jan;56(1):142–150.

Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.

A M Engbersen 1, D G Franken 1, G H Boers 1, E M Stevens 1, F J Trijbels 1, H J Blom 1
PMCID: PMC1801334  PMID: 7825569

Abstract

Thermolability of 5,10-methylenetetrahydrofolate reductase (MTHFR) was examined as a possible cause of mild hyperhomocysteinemia in patients with premature vascular disease. Control subjects and vascular patients with mild hyperhomocysteinemia and with normohomocysteinemia were studied. The mean (+/- SD) specific MTHFR activity in lymphocytes of 22 control subjects was 15.6 (+/- 4.7) nmol CH2O/mg protein/h (range: 9.1-26.6), and the residual activity (+/- SD) after heat inactivation for 5 min at 46 degrees C was 55.3 (+/- 12.0)% (range: 35.9-78.3). By measurement of MTHFR activity, two distinct subgroups of hyperhomocysteinemic patients became evident. One group (n = 11) had thermolabile MTHFR with a mean (+/- SD) specific activity of 8.7 (+/- 2.1) nmol CH2O/mg protein/h (range: 5.5-12.7) and a residual activity, after heat inactivation, ranging from 0% to 33%. The other group (n = 28) had normal specific activity (+/- SD) of 21.5 (+/- 7.2) nmol CH2O/mg protein/h (range: 10.0-39.0) and a normal residual activity (+/- SD) of 53.8 (+/- 9.2)% (range: 33.1-71.5) after heat inactivation. The mean (+/- SD) specific activity of 29 normohomocysteinemic patients was 20.7 (+/- 6.5) nmol CH2O/mg protein/h (range: 9.4-33.8), and the mean (+/- SD) residual activity after heat inactivation was 58.2 (+/- 10.2)% (range: 43.0-82.0). Thus, in 28% of the hyperhomocysteinemic patients with premature vascular disease, abnormal homocysteine metabolism could be attributed to thermolabile MTHFR.

Full text

PDF
142

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benevenga N. J. Betaine in the treatment of homocystinuria. N Engl J Med. 1984 Jan 26;310(4):265–266. doi: 10.1056/NEJM198401263100421. [DOI] [PubMed] [Google Scholar]
  2. Boers G. H., Fowler B., Smals A. G., Trijbels F. J., Leermakers A. I., Kleijer W. J., Kloppenborg P. W. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet. 1985;69(2):164–169. doi: 10.1007/BF00293290. [DOI] [PubMed] [Google Scholar]
  3. Boers G. H., Smals A. G., Trijbels F. J., Fowler B., Bakkeren J. A., Schoonderwaldt H. C., Kleijer W. J., Kloppenborg P. W. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985 Sep 19;313(12):709–715. doi: 10.1056/NEJM198509193131201. [DOI] [PubMed] [Google Scholar]
  4. Brattström L., Lindgren A. Hyperhomocysteinemia as a risk factor for stroke. Neurol Res. 1992;14(2 Suppl):81–84. doi: 10.1080/01616412.1992.11740017. [DOI] [PubMed] [Google Scholar]
  5. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155. doi: 10.1056/NEJM199104253241701. [DOI] [PubMed] [Google Scholar]
  6. Daly L., Robinson K., Tan K. S., Graham I. M. Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med. 1993 Oct;86(10):685–689. doi: 10.1093/qjmed/86.10.685. [DOI] [PubMed] [Google Scholar]
  7. Finkelstein J. D. Methionine metabolism in mammals. J Nutr Biochem. 1990 May;1(5):228–237. doi: 10.1016/0955-2863(90)90070-2. [DOI] [PubMed] [Google Scholar]
  8. Fowler B., Kraus J., Packman S., Rosenberg L. E. Homocystinuria. Evidence for three distinct classes of cystathionine beta-synthase mutants in cultured fibroblasts. J Clin Invest. 1978 Mar;61(3):645–653. doi: 10.1172/JCI108976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Franken D. G., Boers G. H., Blom H. J., Trijbels F. J., Kloppenborg P. W. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994 Mar;14(3):465–470. doi: 10.1161/01.atv.14.3.465. [DOI] [PubMed] [Google Scholar]
  10. Harpey J. P., Rosenblatt D. S., Cooper B. A., Le Moël G., Roy C., Lafourcade J. Homocystinuria caused by 5,10-methylenetetrahydrofolate reductase deficiency: a case in an infant responding to methionine, folinic acid, pyridoxine, and vitamin B12 therapy. J Pediatr. 1981 Feb;98(2):275–278. doi: 10.1016/s0022-3476(81)80660-9. [DOI] [PubMed] [Google Scholar]
  11. Hyland K., Smith I., Bottiglieri T., Perry J., Wendel U., Clayton P. T., Leonard J. V. Demyelination and decreased S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency. Neurology. 1988 Mar;38(3):459–462. doi: 10.1212/wnl.38.3.459. [DOI] [PubMed] [Google Scholar]
  12. Jondal M., Holm G., Wigzell H. Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972 Aug 1;136(2):207–215. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kang S. S., Wong P. W., Bock H. G., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet. 1991 Mar;48(3):546–551. [PMC free article] [PubMed] [Google Scholar]
  14. Kang S. S., Wong P. W., Malinow M. R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279–298. doi: 10.1146/annurev.nu.12.070192.001431. [DOI] [PubMed] [Google Scholar]
  15. Kang S. S., Wong P. W., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991 Mar;48(3):536–545. [PMC free article] [PubMed] [Google Scholar]
  16. Kang S. S., Wong P. W., Zhou J. M., Sora J., Lessick M., Ruggie N., Grcevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988 Jul;37(7):611–613. doi: 10.1016/0026-0495(88)90076-5. [DOI] [PubMed] [Google Scholar]
  17. Kang S. S., Zhou J., Wong P. W., Kowalisyn J., Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988 Oct;43(4):414–421. [PMC free article] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Mudd S. H., Havlik R., Levy H. L., McKusick V. A., Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet. 1981 Nov;33(6):883–893. [PMC free article] [PubMed] [Google Scholar]
  20. Rosenblatt D. S., Erbe R. W. Methylenetetrahydrofolate reductase in cultured human cells. II. Genetic and biochemical studies of methylenetetrahydrofolate reductase deficiency. Pediatr Res. 1977 Nov;11(11):1141–1143. doi: 10.1203/00006450-197711000-00005. [DOI] [PubMed] [Google Scholar]
  21. Ruyter I. E. Release of formaldehyde from denture base polymers. Acta Odontol Scand. 1980;38(1):17–27. doi: 10.3109/00016358008997715. [DOI] [PubMed] [Google Scholar]
  22. Wada Y., Narisawa K., Arakawa T. Infantile type of homocystinuria with 5,10-methylenetetrahydrofolate reductase deficiency. Monogr Hum Genet. 1978;9:140–146. doi: 10.1159/000401626. [DOI] [PubMed] [Google Scholar]
  23. Wendel U., Bremer H. J. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 1984 Jun;142(2):147–150. doi: 10.1007/BF00445602. [DOI] [PubMed] [Google Scholar]
  24. Wendel U., Claussen U., Diekmann E. Prenatal diagnosis for methylenetetrahydrofolate reductase deficiency. J Pediatr. 1983 Jun;102(6):938–940. doi: 10.1016/s0022-3476(83)80029-8. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES